Major Shareholding Shift: Bioretec Ltd Receives Notification from Kustaa Poutiainen

Bioretec Ltd Receives Significant Shareholding Notification

On April 28, 2026, Bioretec Ltd, a pioneer in orthopedic care technology, announced receipt of an important notification in line with Finnish regulatory requirements. This notification, filed under Chapter 9, Section 5 of the Finnish Securities Markets Act, marks a pivotal moment for the company, revealing that Kustaa Poutiainen's controlled entity, Stephen Industries Inc Oy, has increased its holdings in Bioretec to exceed 30% of the company's shares.

Details of the Notification

The notification was triggered by a recent rights issue conducted by Bioretec. This involved both a subscription and an underwriting commitment from Stephen Industries Inc Oy. In conjunction with the offering, the company has also issued 24,196,337 fee shares to Stephen Industries, which has raised their total holdings to 527,891,799 shares — equating to approximately 39.34% of all voting rights within Bioretec.

Previously, as announced on March 26, 2026, the Finnish Financial Supervisory Authority granted a permanent exemption to both Stephen Industries and Kustaa Poutiainen from the requirement to launch a mandatory public takeover bid, even if their holdings were to exceed 30% or 50%. Thus, Bioretec's recent developments will not compel them to pursue such a bid, despite the rising percentage of shares held by one major stakeholder.

Context of the Rights Issue

The rights issue, referred to as the Offering, is a common method employed by companies to raise capital. In Bioretec's scenario, the funds generated are expected to bolster the company's innovative product development initiatives. The issuance of new shares not only reflects a strategy for financial sustainability but also portrays the confidence major stakeholders have in the company's future.

On the same date, it was announced that the newly issued shares have been officially registered with the Finnish Patent and Registration Office, cementing Kustaa Poutiainen’s increasing influence within the company as they navigate this phase of growth.

Bioretec's Market Position and Innovations

Bioretec prides itself on being a global leader in medical device innovation, focusing on fully biodegradable implant technologies that promise to revolutionize orthopedic care. The RemeOs™ product line, characterized by its high-performance magnesium alloy and hybrid composites, enables improved surgical outcomes. These implants are unique in that they get absorbed and replaced by bone, eliminating the need for post-surgical removal and supporting the healing of fractures more effectively.

The Regulatory approvals for the RemeOs product line were milestones in 2023 and 2025, marking Bioretec's commitment to bringing advanced treatment solutions to markets such as the U.S. and Europe. Furthermore, Bioretec's Activa product line includes implants designed from innovative, fully bioabsorbable materials that have garnered both CE and FDA clearances for diverse uses among adult and pediatric populations.

Looking Ahead

As Bioretec continues to expand its reach and enhance its product offerings, the increase in shareholding by Stephen Industries Inc Oy might be seen as a sign of robust investor confidence in its potential. With a total of 1,341,785,963 shares in issue, the company is well-positioned for further developments.

Bioretec is not only focused on immediate corporate growth but is also shaping the future of orthopedic treatment through its commitment to developing patient-friendly and effective medical solutions. The growing influence of key players like Kustaa Poutiainen could facilitate further capital influx, innovation, and ultimately, broader access to its groundbreaking technologies worldwide.

To explore more about Bioretec and its offerings, please visit www.bioretec.com.